Solid Tumors Clinical Trials in Nashville, Tennessee

12 studies are recruiting for solid tumors in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

    The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-u…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Vanderbilt Health One Hundred Oaks Diagnostic ( Site 0060), Nashville, Tennessee
    Locations
    782 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT03486873 on ClinicalTrials.gov

  2. A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

    A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Scri Oncology Partners, Nashville, Tennessee
    Locations
    22 in total
    Run by
    Incyte Corporation

    See if you can join NCT07195916 on ClinicalTrials.gov

  3. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Investigative Site US060, Nashville, Tennessee
    Locations
    229 in total
    Run by
    Incyte Corporation

    See if you can join NCT07522073 on ClinicalTrials.gov

  4. First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

    This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute, Nashville, Tennessee
    Locations
    7 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06644755 on ClinicalTrials.gov

  5. A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

    The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Nashville, Tennessee
    Locations
    25 in total
    Run by
    Arcus Biosciences, Inc.

    See if you can join NCT05536141 on ClinicalTrials.gov

  6. A Study of ZL-1310 in Participants With Selected Solid Tumors

    A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

    Stage
    Phase 1
    Ages
    18 and older
    Site
    SCRI OP (Oncology Partners), Nashville, Tennessee
    Locations
    23 in total
    Run by
    Zai Lab (Shanghai) Co., Ltd.

    See if you can join NCT06885281 on ClinicalTrials.gov

  7. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

    A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee
    Locations
    16 in total
    Run by
    Tyra Biosciences, Inc

    See if you can join NCT06915753 on ClinicalTrials.gov

  8. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

    The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E…

    Stage
    Phase 2
    Ages
    8 and older
    Site
    SCRI - TriStar Medical Group Children's Specialists, Nashville, Tennessee
    Locations
    70 in total
    Run by
    Fore Biotherapeutics

    See if you can join NCT05503797 on ClinicalTrials.gov

  9. A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Scri Oncology Partners, Nashville, Tennessee
    Locations
    34 in total
    Run by
    Incyte Corporation

    See if you can join NCT06179160 on ClinicalTrials.gov

  10. A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

    The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount

    Stage
    Phase 1
    Ages
    18 and older
    Site
    GSK Investigational Site, Nashville, Tennessee
    Locations
    65 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT06431594 on ClinicalTrials.gov

  11. JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

    This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Nashville, Tennessee
    Locations
    15 in total
    Run by
    Jacobio Pharmaceuticals Co., Ltd.

    See if you can join NCT06386146 on ClinicalTrials.gov

  12. QTX3034 in Patients With KRAS G12D Mutation

    Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    SCRI- Nashville, Nashville, Tennessee
    Locations
    14 in total
    Run by
    Quanta Therapeutics

    See if you can join NCT06227377 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.